People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sapience Therapeutics, Inc. | — | Biotechnology | Series B | $30.8M | $317.9M | 2020 |
David Scheinberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Scheinberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Blech | 1 | 14 |
| Robert Ruffolo | 1 | 8 |
| Howard Pien | 1 | 2 |
| Christian Schade | 1 | 2 |
| Barry Kappel | 1 | 1 |
| Robert Ruffolo, Ph.D. | 1 | 1 |
| David Scheinberg, Ph.D. | 1 | 1 |
| Barry Kappel, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.